ZVRAHealthcare · BiotechnologyThe 9 Wall Street analysts covering Zevra Therapeutics, Inc. hold a median 12-month price target of $25 — +132.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 5 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Zevra Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ZVRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +132.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $26 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $24 → $23 |
| 6 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 6 Aug 2026 | Citizens | Maintains | Market Outperform | $25 → $28 |
| 27 July 2026 | BTIG | Maintains | Buy | $27 → $24 |
| 27 July 2026 | BTIG | Maintains | Buy | — |
| 27 July 2026 | Canaccord Genuity | Maintains | Buy | $29 → $20 |
| 27 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 July 2026 | Guggenheim | Maintains | Buy | — |
| 27 July 2026 | Guggenheim | Maintains | Buy | $29 → $24 |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $26 |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 10 June 2026 | Guggenheim | Maintains | Buy | — |
| 10 June 2026 | Maxim Group | Maintains | Buy | — |
| 9 June 2026 | BTIG | Reiterates | Buy | — |
| 9 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | Citizens | Maintains | Market Outperform | — |
| 8 June 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZVRA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Nov 2026, Zevra Therapeutics, Inc. returned +4.6% against +9.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 59% of US stocks
Cheaper than 23% of US stocks
Cheaper than 23% of US stocks
Cheaper than 38% of US stocks
Higher than 86% of US stocks
Higher than 4% of US stocks
Higher than 98% of US stocks
Higher than 93% of US stocks
Higher than 95% of US stocks
Higher than 90% of US stocks
Higher than 90% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zevra Therapeutics, Inc. has a market value of $663.3M and an enterprise value of $389.2M.
Revenue in the twelve months to 30 June 2026: $136.1M. The latest quarter grew 53.3% year on year.
Net income over the same four quarters: $58.3M, a 42.8% net margin.
Free cash flow in the twelve months to 30 June 2026: $32.6M.
Trailing P/E: 9.2×; forward P/E: 10.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Zevra Therapeutics, Inc. employs 61 people — $2.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zevra Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Zevra Therapeutics, Inc.’s Q3 2026 earnings call. The provided excerpt contains no further details from the call.
Why it matters — The transcript is a source for ZVRA watchers seeking the company’s Q3 2026 earnings-call discussion, but no specific updates are included in the excerpt.
Zevra Therapeutics reported quarterly earnings of $0.18 per share, above the Zacks Consensus Estimate of $0.14. This compares with a loss of $0.01 per share a year earlier.
Why it matters — ZVRA watchers may note the quarterly earnings beat and the year-over-year change in per-share results.
Zevra Therapeutics reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million a year earlier. The increase was driven primarily by U.S. sales of MIPLYFFA for Niemann-Pick disease type C.
Why it matters — The report highlights year-over-year revenue growth and the contribution of U.S. MIPLYFFA sales to ZVRA’s quarterly revenue.
Zevra Therapeutics reported $37.8 million in net revenue for the third quarter of 2026, including $34.0 million from MIPLYFFA.
Why it matters — The reported revenue and MIPLYFFA contribution provide ZVRA watchers with a snapshot of the company’s quarterly financial performance.
Zevra Therapeutics announced it will report third-quarter 2026 corporate and financial results in a news release after market close on November 3, 2026. The company will host a conference call and audio webcast at 4:30 p.m. ET that day.
Why it matters — ZVRA watchers can note the scheduled date and time for the company's third-quarter results and related discussion.
The 9 Wall Street analysts covering Zevra Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $20 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Zevra Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zevra Therapeutics, Inc. 96 out of 100 across roughly 4,600 US stocks as at 5 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Nov 2026, Zevra Therapeutics, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +132.7% from the last close, and Ticker Nerd's factor model ranks Zevra Therapeutics, Inc. 96 out of 100 as at 5 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zevra Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZVRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $35 over the next 12 months.
Zevra Therapeutics, Inc. returned +4.6% over the 12 months to 5 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Zevra Therapeutics, Inc.’s Q3 2026 earnings call. The provided excerpt contains no further details from the call.
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases. Its current business centers on developing and commercializing therapies for patients with serious conditions that have limited or no treatment options, with approved products and late-stage assets spanning Niemann-Pick disease type C, urea cycle disorders, and related neurological and metabolic disorders. The company’s portfolio includes marketed medicines, active clinical programs, and partnership-derived royalty interests, reflecting a model that combines direct product commercialization with pipeline development. Zevra Therapeutics also uses its Ligand Activated Technology platform to support product development. Headquartered in the United States, Zevra Therapeutics plays a focused role in the rare disease market by advancing specialized treatments for patient populations with significant unmet medical needs.
CEO Mr. Neil F. McFarlane · 61 employees · United States · https://www.zevra.com
